Physician profile
Patrick E Matoole
NPI 1588668149
$13,696.84
in general payments reported to CMS, 2019-2025
68 companies · $2,459 in 2025
The $2,459 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,305 · 2020: $1,586 · 2021: $1,956 · 2022: $1,773 · 2023: $2,147 · 2024: $2,471 · 2025: $2,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,076.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,293.09 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,199.11 | 2019-2025 | |
| Biogen, INC. | $1,020.23 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Ucb, INC. | $981.92 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Eisai INC. | $548.07 | 2019-2025 | |
| Mdd US Operations, LLC | $525.01 | 2019-2025 | Apokyn, Apokyn |
| Jazz Pharmaceuticals INC. | $519.15 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $439.02 | 2019-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $397.52 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Amgen INC. | $378.18 | 2019-2025 | Aimovig, Uplizna |
| Sk Life Science, INC. | $361.79 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $345.03 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $282.24 | 2019-2025 | Ultomiris, Soliris |
| Harmony Biosciences LLC | $282.19 | 2020-2025 | Wakix |
| Pfizer INC. | $279.76 | 2019-2025 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Matoole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.